AbbVie is +27% over the past year while the S&P 500 is +18%: 9.2 points ahead of the market. 1-year return: +27% (S&P 500 +18%). vs 200-day average: +20%, a clear uptrend. RSI (14): 72, overbought, bought harder than it has been sold. Below its 52-week high: 0.00%.

ABBVAbbVie

Healthcare

$276.40+27% 1Y

$276.40

$197.3852 weeks$276.40

Latest close: a new 52-week highOct 9, 2026what changed →

What is the market doing?

Mixed

No clear lean: nothing decisive, though in an uptrend.

1 good, 2 neutral

TrendUptrendderived · Oct 9, 2026

In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 72). Price is +20% vs its 200-day average.

Insider conviction−$8.2M (90 days to Oct 8, 2026)SEC EDGAR · Oct 8, 2026

Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).

Short interest1.1% of sharesFINRA · Sep 15, 2026

Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Level with the previous count, down from 1.3% of shares outstanding three months ago.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returnbetter than 70% of the market

vs 200-day avgbetter than 85% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How ABBV is trading

AbbVie is +27% over the past year while the S&P 500 is +18%: 9.2 points ahead of the market.

+27%

1-year return · S&P 500 +18%

vs 200-day average: +20%
vs 200-day average · a clear uptrend
RSI (14): 72
RSI (14) · overbought, bought harder than it has been sold
Below its 52-week high: 0.00%
Below its 52-week high

Sep 17, 2024$156.84 – $276.40 · dashed line: 200-day averageOct 9, 2026

Details›

Last close2026-10-09: $276.40
1 monthS&P 500 +2.7%: +8.4%
1 yearS&P 500 +18%: +27%
5 yearsS&P 500 +88%: +207%
vs 50-day average$259.12: +6.7%
52-week high: $276.40
52-week low: $197.38
Annualised volatility: 27%
Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08: −$8.2M

Calendar-year price return
Year	Return
2026 (year to date)	+23%
2025	+33%
2024	+19%
2023	−0.23%
2022	+24%
2021	+32%
2020	+28%
2019	+1.5%
2018	−0.96%
2017	+60%

Average return by calendar month, 2016–2026
Month	Years	Positive	Average
Jan	10	4 of 10	−0.25%
Feb	10	9 of 10	+5.1%
Mar	10	7 of 10	−1.1%
Apr	10	4 of 10	−1.2%
May	10	6 of 10	+0.27%
Jun	10	5 of 10	+1.9%
Jul	11	7 of 11	+2.9%
Aug	11	6 of 11	+1.7%
Sep	11	6 of 11	+2.3%
Oct	11	6 of 11	−0.21%
Nov	10	9 of 10	+7.6%
Dec	10	7 of 10	+2.8%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

On our screens:Quality at a reasonable price Stocks that buy back more than they dilute

Drug Manufacturers, General

The closest names by size in the same industry